Art

J-GLOBAL ID：201702237383339220   Reference number：17A1492849

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

白金感受性の再発卵巣癌とBRCA1/2変異(SOLO2/ENGOT Ov21)患者における維持療法としてのオラパリブ錠:二重盲検,無作為化,プラセボ対照,第3相試験【Powered by NICT】

Author (20)： Pujade-Lauraine Eric (Medical Oncology Department, Universite Paris Descartes, AP-HP, Paris, France) ,  Ledermann Jonathan A (Department of Oncology, University College London, London, UK) ,  Selle Frederic (Hopital Tenon, Paris, France) ,  Gebski Val (Department of Biostatistics and Research Methodology, University of Sydney, Sydney, NSW, Australia) ,  Penson Richard T (Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA) ,  Oza Amit M (Princess Margaret Cancer Centre, Toronto, Canada) ,  Korach Jacob (Gynecologic Oncology Department, Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel) ,  Huzarski Tomasz (Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland) ,  Poveda Andres (Instituto Valenciano de Oncologia, Valencia, Spain) ,  Pignata Sandro (Istituto Tumori Pascale di Napoli, Naples, Italy) ,  Friedlander Michael (Department of Medical Oncology, University of New South Wales Clinical School, Prince of Wales Hospital, Randwick, NSW, Australia) ,  Colombo Nicoletta (Gynecology Department, University of Milan-Bicocca and Istituto Europeo Oncologia, Milan, Italy) ,  Harter Philipp (Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany) ,  Fujiwara Keiichi (Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan) ,  Ray-Coquard Isabelle (Medical Oncology Department, Centre Leon Berard and University Claude Bernard, Lyon, France) ,  Banerjee Susana (The Royal Marsden NHS Foundation Trust, London, UK) ,  Liu Joyce (Dana-Farber Cancer Institute, Boston, MA, USA) ,  Lowe Elizabeth S (AstraZeneca, Gaithersburg, MD, USA) ,  Bloomfield Ralph (AstraZeneca, Cambridge, UK) ,  Pautier Patricia (Gustave Roussy Cancer Campus, Villejuif, France)
Material： Lancet Oncology  (Lancet Oncol)
Volume： 18  Issue： 9  Page： 1274-1284  Publication year： 2017 
JST Material Number： W1266A  ISSN： 1470-2045  Document type： Article
Article type： 原著論文  Country of issue： Netherlands (NLD)  Language： ENGLISH (EN)

Abstract/Point： Olaparib, a poly(ADP-ribose) p...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1492849&from=J-GLOBAL&jstjournalNo=W1266A") }}

Thesaurus term： *Recurrence ,  Anemia ,  *ovarian tumor ,  quality of life ,  *double blind test ,  *patient ,  data analysis ,  toxicity ,  *placebo ,  *sensitivity ,  drug therapy ,  phase 2 study ,  *phase 3 study ,  adverse reaction ,  enzyme inhibitor ,  molecular targeting drug
Semi thesaurus term： 有害事象 , 【Automatic Indexing@JST】

JST classification (1)： Treatment for tumors in general  (GE03031L)

Substance index (1)： Olaparib

Terms in the title (12)： 白金 ,  感受性 ,  再発卵巣癌 ,  BRCA1 ,  変異 ,  患者 ,  維持療法 ,  オラパリブ ,  二重盲検 ,  プラセボ ,  対照 ,  第3相試験